# Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma

> **NCT00191503** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (—)

## Conditions studied

- Adenocarcinoma

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00191503
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 30 (—)
- **Last updated:** 2007-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191503, "Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00191503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*